Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Cancer

• Publication date

  2025-03-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s43018-025-00930-5PMID 40075237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supramolecular Lipid Nanoparticles Based on Host–Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy

  2024influential reference
• Translational Studies Using the MALT1 Inhibitor (S)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer

  2023cited by this paper
• A timeline of tumour-associated macrophage biology

  2023cited by this paper
• Tumor-derived Jagged1 promotes cancer progression through immune evasion.

  2022cited by this paper
• Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

  2021cited by this paper
• Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme

  2021cited by this paper
• MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer.

  2021cited by this paper
• Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.

  2021cited by this paper
• Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.

  2021cited by this paper
• PD-1/PD-L1 pathway: current researches in cancer.

  2020cited by this paper
• Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.

  2020cited by this paper
• PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model

  2020cited by this paper
• Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

  2019cited by this paper
• Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

  2019influential reference
• MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.

  2019cited by this paper
• Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment.

  2019cited by this paper
• Tumour-intrinsic resistance to immune checkpoint blockade

  2019cited by this paper
• Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

  2019cited by this paper
• Malt1 Protease Is Critical in Maintaining Function of Regulatory T Cells and May Be a Therapeutic Target for Antitumor Immunity

  2019cited by this paper
• Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

  2019cited by this paper
• Therapeutic Antisense Oligonucleotides Are Coming of Age.

  2019cited by this paper
• Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion

  2018influential reference
• Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

  2018cited by this paper
• Molecular architecture and regulation of BCL10-MALT1 filaments

  2018cited by this paper
• The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

  2018cited by this paper
• Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors

  2018cited by this paper
• Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

  2018cited by this paper
• The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.

  2018cited by this paper
• A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

  2018cited by this paper
• Leading Edge Review Primary , Adaptive , and Acquired Resistance to Cancer Immunotherapy

  2017influential reference
• Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

  2016cited by this paper
• Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

  2016cited by this paper
• MALT1 is required for EGFR induced NF-κB activation and contributes to EGFR-driven lung cancer progression

  2015cited by this paper
• Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation

  2014cited by this paper
• Complement, C1q, and C1q-Related Molecules Regulate Macrophage Polarization

  2014cited by this paper
• Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

  2013cited by this paper
• Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation.

  2013cited by this paper
• Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.

  2013cited by this paper
• Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

  2012cited by this paper
• Complement Protein C1q Directs Macrophage Polarization and Limits Inflammasome Activity during the Uptake of Apoptotic Cells

  2012cited by this paper
• MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

  2012cited by this paper
• RNA therapeutics: beyond RNA interference and antisense oligonucleotides

  2012cited by this paper
• NF-κB signaling pathways regulated by CARMA family of scaffold proteins

  2011cited by this paper
• T‐cell receptor‐induced JNK activation requires proteolytic inactivation of CYLD by MALT1

  2011cited by this paper
• Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines

  2011cited by this paper
• T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20

  2008cited by this paper
• The proteolytic activity of the paracaspase MALT1 is key in T cell activation

  2008cited by this paper
• Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.

  2005cited by this paper
• CSF-1 regulation of the wandering macrophage: complexity in action.

  2004cited by this paper
• The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.

  2004cited by this paper
• Differential requirement for Malt1 in T and B cell antigen receptor signaling.

  2003cited by this paper
• Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-κB Signaling Pathway*

  2001cited by this paper
• Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma.

  2000cited by this paper
• Screening

  2000cited by this paper

• Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer

  2026cites this paper
• ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC-I Antigen Presentation That Promotes Tumor Immune Evasion.

  2026cites this paper
• Chemoresistance Evolution in Ovarian Cancer Delineated by Single-Cell RNA Sequencing

  2025influential citation
• MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors

  2025cites this paper
• PD-1 blockade elicits a systemic immune response but not in the tumor of TNBC mice.

  2025cites this paper
• Recent Development in NSCLC Immunotherapies: Mechanisms, Advantages and Research Findings

  2025cites this paper
• Breaking the oncogenic link: BCL10–MALT1 disruption as a precision strike against NF-κB-driven lymphomas

  2025cites this paper